Keryx appoints interim chairman, CEO
NEW YORK Drug maker Keryx Pharmaceuticals has appointed Michael Tarnok as its interim chairman and CEO, the company announced Thursday.
Tarnok, who has served on Keryx’s board of directors since September 2007, will replace Michael Weiss.
Tarnok spent most of his career working at Pfizer, having joined that company as finance director for U.S. manufacturing in 1989 and serving as SVP finance in its U.S. pharmaceuticals division from 2000 to 2007.
Eli Lilly & Co. granted preliminary injunction against Teva
INDIANAPOLIS A U.S. District Court has granted drug maker Eli Lilly & Co. a preliminary injunction preventing the launch of a generic version of one of its drugs, Lilly announced Wednesday.
The company said the U.S. District Court for the Southern District of Indiana issued the injunction to prevent Teva Pharmaceuticals’ launch of raloxifene hydrochloride tablets, a generic version of Lilly’s osteoporosis drug Evista.
Patents on Evista begin expiring in 2012. The drug had sales of $700.5 million in 2008, according to Lilly financial data.
DFB Pharmaceuticals appoints new VP business development, corporate finance
FORT WORTH, Texas DFB Pharmaceuticals announced Thursday that it promoted Maxwell Lea to VP business development and corporate finance.
Lea most recently served as director of corporate development and finance for the company. As vice president, he will manage DFB’s capital raising and financing activities, business development initiatives and strategic planning. He will also be responsible for business development efforts for DFB affiliate Healthpoint.
“Since joining DFB in 2002, Maxwell has positively impacted every level of our company and its affiliate businesses,” CFO Michael Patterson said. “I can say without reservation that our companies have excelled due to his success.”